Abstract

EFFICACY OF BILASTINE AND MONTELUKAST COMBINATION IN PATIENTS WITH COUGH DUE TO RESPIRATORY DISEASES

Dr. Hadiya Iram*, Swathi Surigi, B.H.N.S. Geetanjali, Kolan Manisha, Dr. V. Raja Manohar Acharyulu

.

Abstract

Background: Coughing is a natural reflex that helps clear out our airways, but when it sticks around, it could be a sign of something more serious, like infections, allergies, or chronic respiratory issues. Getting an accurate diagnosis is really important because there are so many potential causes. To tackle both inflammation and allergy-related coughs, a combination treatment called BILASTINE+MONTELUKAST has been developed. Montelukast works to reduce inflammation in the airways and cut down on mucus production, while Bilastine, an antihistamine, helps ease allergy symptoms by blocking histamine. This two-pronged approach provides a thorough solution for managing coughs associated with respiratory and allergic conditions. Methodology: The prospective observational study, conducted 6 months at Medicover Hospitals, the study included 80 participants aged above 18 years experiencing respiratory symptoms. The exclusions included conditions such as pregnancy and Nuero-psychiatric disorders. The data gathered covered demographics, lifestyle factors, biomarkers (like PFTs, ECG, AEC, and Total IgE), chest X-rays, and side effects from medications. Patients dealing with respiratory issues were given Bilastine 20 mg and Montelukast 10 mg. After two weeks, follow-ups were conducted to evaluate the treatment's effectiveness using a quality-of-life questionnaire. Statistical analysis was performed to assess how well the combination worked in managing respiratory diseases. Data was statistically analyzed using SPSS Version 22.1. Results and Discussion: We have used the Leicester Cough Questionnaire (LCQ) to assess the results. The combination treatment proved to be quite effective, with 60 out of 80 patients (75%) finding relief within just 1-2 weeks, and an average relief rate of 78.5% (SD: 12.1%). This aligns well with other studies that have shown efficacy rates between 70% and 85%, with an average relief rate of 74.2% (SD: 15.6%) for similar combination therapies aimed at allergic rhinitis. All in all, this therapy significantly reduced cough-related symptoms and improved the overall quality of life for the patients. Conclusion: These findings indicate that patients who received a combination therapy of Bilastine and Montelukast experienced positive outcomes, along with an enhanced quality of life. These results combined with earlier research highlighting the potential advantages of both medications in treating allergic rhinitis and chronic cough, provide valuable insights.

Keywords: Cough, Bilastine, Montelukast, Respiratory diseases, Efficacy.